Lance Sullenberger is a Cardiology physician affiliated with Capital Cardiology Associates. OpenAlex indexes 27 publications with 1,481 citations (h-index 10).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingIndustry payments
53 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
53 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
94.5%Other lipid modifying agents64.2%Inclisiran100%Icosapent Ethyl0%Part D + Part B<11 patientsStatin7.9%Atorvastatin Calcium57%Rosuvastatin Calcium34%Pravastatin Sodium5%Simvastatin3%Livalo0%Lovastatin0%Crestor0%Part D<11 patients+ 24 more classes in this area
Blood & clotting
3.2%Factor Xa inhibitor2.5%Eliquis86%Xarelto14%Part D≥444 patientsP2Y12 inhibitor0.7%Clopidogrel91%Prasugrel Hcl6%Brilinta3%Part D<11 patientsMetabolism & gastrointestinal
2.1%SGLT2 inhibitor0.9%Jardiance89%Farxiga11%Part D≥183 patientsPotassium supplement0.6%Potassium Chloride78%Klor-Con M2022%Part D≥100 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Evaluating the Appropriate Use Criteria for Coronary Revascularization in Stable Ischemic Heart Disease Using Randomized Data From the ISCHEMIA Trial
Circulation Cardiovascular Quality and Outcomes
2025 - Artificial intelligence-guided coronary computed tomography angiography: treatment recommendations vs. real-world prescriptions
European Journal of Preventive Cardiology
2025 - Impact of atherosclerosis imaging-quantitative computed tomography on diagnostic certainty, downstream testing, coronary revascularization, and medical therapy: the CERTAIN study
European Heart Journal - Cardiovascular Imaging
2024 - Sex Differences in Revascularization, Treatment Goals, and Outcomes of Patients With Chronic Coronary Disease: Insights From the ISCHEMIA Trial
Journal of the American Heart Association
2024
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”